A rare case of superior ophthalmic vein thrombosis and thrombocytopenia following ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 Ophthalmic vein thrombosis following Covid

Main Article Content

Irina Panovska-Stavridis


COVID, Ophthalmic vein thrombosis, thrombocytopenia




Download data is not yet available.

Abstract 822
PDF Downloads 267
HTML Downloads 311


1. WHO. WHO target product profiles for COVID-19 vaccines April 9, 2020. https://www.who.int/publications/m/item/whotarget-product-profiles-for-covid-19-vaccines (accessed, Maj 5, 2021).
2. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021 J; 397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1.
3. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021 Apr 9; NEJMoa2104840. doi: 10.1056/NEJMoa2104840
4. Pai M, Chan B, Stall NM, et al. Vaccine-induced immune thrombotic thrombocytopenia (VITT) following adenovirus vector COVID-19 vaccination. Science Briefs of the Ontario COVID-19 Science Advisory Table. 2021;2(17):1-7. https://doi.org/10.47326/ ocsat.2021.
5. Bayas A, Menacher M2, Christ M, et al. Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination
Lancet 2021 May 1; 397(10285):e11. doi: 10.1016/S0140-6736(21)00872-2.
6. Strobel E. Use of the ID-PaGIA Heparin/PF4 Antibody Test as a screening test for heparin/platelet factor 4 antibodies. Blood Transfus. 2017;15(3):268-271. doi:10.2450/2016.0302-15
7. https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood (accessed, Maj 5, 2021)
8. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine (accessed, Maj 5, 2021)